Clinical Trials Directory

Trials / Completed

CompletedNCT01051960

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
12 (actual)
Sponsor
University of California, Los Angeles · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects with exercise induced Pulmonary Arterial Hypertension (PAH) with scleroderma

Detailed description

The current literature addresses therapies for patients with resting PAH only, diagnosed by right heart catheterization. However, the World Health Organization (WHO) also recognizes and defines exercise induced pulmonary arterial hypertension (ex-PAH), which may precede the development of resting PAH. The natural progression of PAH, especially during exercise, has not been well delineated. An exercise hemodynamic study previously showed that in normal healthy subjects the mean pulmonary pressure does not exceed 30mmHg even at maximal cardiac outputs. A prior study evaluated exercise Doppler echocardiography systemic sclerosis patients with normal resting echocardiograms, finding an abnormal response which was defined as an estimated right ventricular systolic pressure greater than 40 mmHg. In the same study, 6.6% of the patients progressed to resting PAH over the followup period of 12 months. Limited data is available regarding the prevalence of ex-PAH in systemic sclerosis using right heart catheterization.

Conditions

Interventions

TypeNameDescription
DRUGAmbrisentanAmbrisentan 5mg or 10mg once daily

Timeline

Start date
2009-03-01
Primary completion
2010-06-01
Completion
2011-01-01
First posted
2010-01-20
Last updated
2020-11-02
Results posted
2020-11-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01051960. Inclusion in this directory is not an endorsement.